Patents

---

---

Modulation of stem and progenitor cell differentiation, assays, and uses thereof

Patent Number: 7,498,171
One of the areas in which regenerative medicine is heading is the use of "drugs" to modulate the stem cell compartment.  For example, we have previously seen companies like Stem Cell Therapeutics performing clinical trials with EPO and hCG for stroke.  Drugs already in the clinic such as Velcade, have also been...

Inventors: Hariri; Robert J. (Florham Park, NJ), Stirling; David I. (Warren, NJ), Moutouh-De Parseval; Laure A. (San Diego, CA), Chan; Kyle W. H. (San Diego, CA)

Assignee: Anthrogenesis Corporation (Warren, NJ)

Date of First Priority Issue: Friday April 12th, 2002

---

Compounds modulating c-kit activity

Patent Number: 7,498,342
c-kit is involved in hematopoietic stem cell self-renewal, however it is also found in other stem cells as well.  For example, cardiac stem cells express c-kit.  This is an exciting drug target and other companies have patents covering its inhibitors, for example, #7,211,600 by Sugen.The current patent covers composition of...

---

Mammalian megakaryocyte progenitor cell

Patent Number: 7,494,807
This patent covers methods of isolating the megakaryocytic progenitor cells through selecting for cells that are positive for  CD41, CD, and CD34 and negative for expression of CD2; CD3; CD4; CD7; CD8; CD10; CD11b; CD14; CD19; CD20; CD56; and glycophorin A.  Starting materials for selection of these cells include bone marrow and mobilized peripheral blood.Platelet deficiency is a major...

---

Methods and compositions for correction of cardiac conduction disturbances

Patent Number: 7,494,644
It is known that bone marrow stem cells are mobilized after heart injury such as infarct, with presumable therapeutic effects mediated by the stem cells in terms of stimulating angiogenesis or even integrating into the damaged myocardium and transdifferentiating into de novo cardiomyocytes.  One of the...

---

Methods for altering cell fate to generate T-cells specific for an antigen of interest

Patent Number: 7,491,534
The concept of taking one cell and turning it into another cell has been reported and even patented in certain situations, however, it is still difficult to see examples of wide-spread use of such techniques.  For example, patent #6,087,168 covers transdifferentiation of epidermal cells into neurons by transfection with some specific neuronal transcription...

---

Uses of fibroblasts or supernatants from fibroblasts for the suppression of immune responses in transplantation

Patent Number: 7,491,388
We know that mesenchymal stem cells are immune modulatory through a variety of means such as secretion of HLA-G, expression of indolamine 2,3 deoxygenase, and production of immune suppressive cytokines.  What is relatively understudied is the immune regulatory activities of fibroblasts.  For example...

---

Use of glycosylceramides as adjuvants for vaccines against infections and cancer

Patent Number: 7,488,491
This patent covers the use of a novel stimulator of natural killer t (NKT) cells which are known to be involved in activation of both dendritic cells and T cells.  Interestingly NKT cells are also involved in the liver and possibility development of fibrosis. The first independent claim of this patent is "A method for augmenting...

---

Wound and cutaneous injury healing with a nucleic acid encoding perlecan

Patent Number: 7,488,719
This patent covers methods of acceleration of wound healing by transfecting cells with nucleic acids encoding the extracellular molecule perlecan.  Perlecan is associated with extracellular matrices in stem cell niches such as the limbic epithelial stem cell compartment (Schlotzer-Schrehardt et al. Characterization of extracellular matrix components in the limbal epithelial stem cell...

---

PSCA: prostate stem cell antigen and uses thereof in pancreatic cancer

Patent Number: 7,485,296
The current patent covers "A method for treating a patient having pancreatic cancer by inhibiting the growth of a pancreatic cancer cell expressing the Prostate Stem Cell Antigen (PSCA) protein as shown in SEQ ID NO: 2 in the patient, comprising contacting the pancreatic cancer cell with the monoclonal antibody 1G8 (ATCC No. HB-12612), or a fragment thereof that recognizes and binds PSCA as...

---

Enhanced growth of adult stem cells with Dkk-1

Patent Number: 7,485,460
Although mesenchymal stem cells, or mesenchymal stromal cells (as some others call them), are in late stages of clinical development, there is still room for optimizing their therapeutic effects.  For example, various groups have transfected MSC with genes such as nanog or bcl-2 or Inventors: Prockop; Darwin (Philadelphia, PA), Sekiya; Ichiro (Tokyo, JP), Gregory; Carl (New Orleans, LA), Spees; Jeffrey (New Orleans, LA), Smith; Jason (New Orleans, PA), Pochampally; Radhika (Marrero, LA)

Order by: Title Comments Assignee Inventor Patent Number First Priority Date Issued Updated Desc Desc Asc 10 10 25 50 100 250 All

<< | < | 1 2 3 4 5 6 7 8 9 | > | >>